|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Luminex Corporation (NASDAQ:LMNX), a developer of proprietary biological testing technologies. |
|---|---|
| Transferring Party | Tm Bioscience Corporation (TSX: TMC), a Toronto-based diagnostics company developing a suite of DNA-based tests for genetic disorders, drug metabolism and infectious diseases |
| Sector | Diagnostics |
| Date | March 2, 2007 |
| Analysis Furthers Luminex's goal to be a leader in the fast growing molecular diagnostics market. Tm has proprietary technologies that improve the speed, accuracy, flexibility, and cost of DNA-based genetic tests. Tm's cystic fibrosis test is the first multiplexed human disease genotyping test to be cleared by the FDA for diagnostic use in the U.S. Deal value - US$44. Tm's revenue is about US$14m (3.1x). | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2010 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |